Impact of denosumab on bone high-resolution peripheral quantitative computed tomography (HRpQCT) in hemodialysis patients: a retrospective longitudinal observational study

Clicks: 21
ID: 329379
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #135 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Hypothesis Denosumab increases bone mineral density (BMD) in dialysis patients, but the effects on bone microarchitecture using high-resolution peripheral quantitative computed tomography (HRpQCT) and the response factors to treatment are unknown. Methods We analyzed, at a single centre between 2014 and 2024, 19 consecutive patients on hemodialysis having a longitudinal HRpQCT monitoring at the distal tibia and radius. After excluding the presence of osteomalacia based on bone biopsies and ensuring well-controlled parathyroid hormone (PTH) levels, 9 patients with recent fractures were treated with denosumab. Changes in HRpQCT parameters observed over time were analyzed within the denosumab group and were compared to a group of a non-treated patients, using linear mixed models for repeated measures. Baseline histomorphometric parameters were analyzed as predictors of changes in HRpQCT parameters over time in denosumab-treated patients. Results During a median [maximum—minimum] follow-up period of 2.1 [1.0–3.5] years, the 9 denosumab-treated patients had a significant improvement of (i) bone volume to total volume ratio at the distal radius (+1.63% [95% Confidence Interval : 1.11–3.31] per year, p = 0.037) and tibia (+1.13% [0.10–2.28], p = 0.049) , (ii) trabecular volumetric BMD at the distal radius (+1.58 [1.07–3.30], p = 0.039) and tibia (+0.95% [0.11–1.97], p = 0.039), (iii) trabecular number at the distal radius (+1.86% [0.45–3.28], p = 0.017), and (iv) trabecular separation at the distal radius (-1.83% [-3.16–-0.50], p = 0.014). These changes were also significant when compared with those of the untreated group. Changes in cortical parameters did not change significantly over time. At most, changes in trabecular volumetric BMD at the radius was negatively associated with osteoid volume. Conclusion Denosumab improves HRpQCT trabecular bone parameters without significant effect on cortical parameters in dialysis patients.
Reference Key
openalex_W7213983514 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Benjamin Batteux, Ana Pimentel, Agnès Ostertag, Tilman Bernhard Drüeke, Martine Esther Cohen-Solal, Pablo Antonio Ureña Torres
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag182
URL
https://doi.org/10.1093/ckj/sfag182
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.